Affimed Announces Completion of Enrollment in REDIRECT, the Registration-Directed Study of AFM13 in PTCL, and Provides Business Update January 6, 2022
Affimed Shares Preclinical Data on Innate Cell Engagers AFM28 and AFM13 at the 63rd American Society of Hematology Annual Meeting and Exposition December 13, 2021
Affimed to Host Virtual Investor Call Today to Discuss Treatment of CD30-positive Lymphoma Patients with Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13 December 9, 2021
Affimed Initiates Patient Recruitment for a Phase 1/2a Trial of Innate Cell Engager AFM24 in Combination with Roche’s Anti-PD-L1 Checkpoint Inhibitor Atezolizumab December 8, 2021
Affimed Announces 100% Objective Response Rate at Highest Dose in Phase 1-2 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13 for CD30-positive Lymphomas November 22, 2021
Affimed Shares Preclinical Data on Mechanism of Action of two Innate Cell Engagers at the 36th SITC Meeting, Demonstrating their Potential to Induce Antibody Dependent Cellular Phagocytosis and Serial Killing November 12, 2021
Affimed Reports Third Quarter 2021 Financial Results and Highlights Operational Progress November 10, 2021